NASDAQ:ANNX Annexon (ANNX) Stock Price, News & Analysis $2.51 -0.04 (-1.57%) Closing price 07/25/2025 04:00 PM EasternExtended Trading$2.50 0.00 (-0.20%) As of 07/25/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Annexon Stock (NASDAQ:ANNX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Annexon alerts:Sign Up Key Stats Today's Range$2.46▼$2.5850-Day Range$1.97▼$2.9652-Week Range$1.28▼$7.85Volume764,532 shsAverage Volume1.90 million shsMarket Capitalization$275.37 millionP/E RatioN/ADividend YieldN/APrice Target$12.50Consensus RatingBuy Company Overview Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California. Read More Annexon Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreANNX MarketRank™: Annexon scored higher than 49% of companies evaluated by MarketBeat, and ranked 583rd out of 936 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAnnexon has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAnnexon has only been the subject of 2 research reports in the past 90 days.Read more about Annexon's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Annexon are expected to decrease in the coming year, from ($0.96) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Annexon is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Annexon is -2.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnnexon has a P/B Ratio of 0.91. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Annexon's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.39% of the float of Annexon has been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Annexon has recently decreased by 0.69%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAnnexon does not currently pay a dividend.Dividend GrowthAnnexon does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.39% of the float of Annexon has been sold short.Short Interest Ratio / Days to CoverAnnexon has a short interest ratio ("days to cover") of 5.9.Change versus previous monthShort interest in Annexon has recently decreased by 0.69%, indicating that investor sentiment is improving. News and Social Media1.8 / 5News Sentiment0.29 News SentimentAnnexon has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.09 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Annexon this week, compared to 3 articles on an average week.Search InterestOnly 3 people have searched for ANNX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows1 people have added Annexon to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Annexon insiders have sold 57.81% more of their company's stock than they have bought. Specifically, they have bought $10,123.00 in company stock and sold $15,975.00 in company stock.Percentage Held by Insiders11.87% of the stock of Annexon is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Annexon's insider trading history. Receive ANNX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Annexon and its competitors with MarketBeat's FREE daily newsletter. Email Address ANNX Stock News HeadlinesAnnexon, Inc. (NASDAQ:ANNX) Director Purchases $10,122.90 in StockJuly 2, 2025 | insidertrades.comAnnexon Announces Completion of Enrollment in Pivotal Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry Age-Related Macular Degeneration (AMD) with Geographic AtrophyJuly 24 at 7:00 AM | globenewswire.comGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bill Gates has backed four companies in this space. The World Economic Forum calls it “the most exciting human discovery since fire.” Whitney Tilson believes this trend could mint a new class of wealthy investors—and he’s sharing one stock to watch now, for free.July 27 at 2:00 AM | Stansberry Research (Ad)Annexon: Lead GBS Therapy Stokes Near-Term PotentialJuly 14, 2025 | seekingalpha.comNoteworthy Thursday Option Activity: ANNX, SPOT, STNGJuly 12, 2025 | nasdaq.comAnnexon, Inc. (ANNX) Latest Stock News & Headlines - Yahoo FinanceJuly 11, 2025 | finance.yahoo.comAnnexon Biosciences to Present at the Jefferies Global Healthcare ConferenceMay 29, 2025 | globenewswire.comAnnexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual MeetingMay 19, 2025 | globenewswire.comSee More Headlines ANNX Stock Analysis - Frequently Asked Questions How have ANNX shares performed this year? Annexon's stock was trading at $5.13 on January 1st, 2025. Since then, ANNX stock has decreased by 51.1% and is now trading at $2.51. How were Annexon's earnings last quarter? Annexon, Inc. (NASDAQ:ANNX) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.30) by $0.07. When did Annexon IPO? Annexon (ANNX) raised $150 million in an initial public offering on Friday, July 24th 2020. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Cowen served as the underwriters for the IPO. Who are Annexon's major shareholders? Top institutional shareholders of Annexon include J. Safra Sarasin Holding AG (0.35%), Park Avenue Securities LLC (0.10%), CWM LLC (0.02%) and Vanguard Personalized Indexing Management LLC (0.01%). Insiders that own company stock include Muneer A Satter, Bain Capital Life Sciences Inv, Douglas Love, Michael Overdorf, Jennifer Lew, Ted Yednock, Dean Richard Artis, Jamie Dananberg and William H Carson. View institutional ownership trends. How do I buy shares of Annexon? Shares of ANNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Annexon own? Based on aggregate information from My MarketBeat watchlists, some other companies that Annexon investors own include NVIDIA (NVDA), MercadoLibre (MELI), Advanced Micro Devices (AMD), Meta Platforms (META), CRISPR Therapeutics (CRSP) and Energy Transfer (ET). Company Calendar Last Earnings5/12/2025Today7/27/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ANNX CIK1528115 Webwww.annexonbio.com Phone650-822-5500Fax650-636-9773Employees60Year FoundedN/APrice Target and Rating Average Price Target for Annexon$12.50 High Price Target$14.00 Low Price Target$11.00 Potential Upside/Downside+398.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.18) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$138.20 million Net MarginsN/A Pretax MarginN/A Return on Equity-54.45% Return on Assets-46.56% Debt Debt-to-Equity RatioN/A Current Ratio7.99 Quick Ratio7.99 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.75 per share Price / Book0.91Miscellaneous Outstanding Shares109,710,000Free Float96,691,000Market Cap$275.37 million OptionableOptionable Beta1.30 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:ANNX) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.